Ameritas Investment Partners, Inc. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
Ameritas Investment Partners, Inc. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$75,384
+197.6%
4,066
+77.6%
0.00%
+200.0%
Q2 2023$25,327
-17.6%
2,2900.0%0.00%0.0%
Q1 2023$30,755
-15.6%
2,2900.0%0.00%0.0%
Q4 2022$36,434
+17.5%
2,2900.0%0.00%0.0%
Q3 2022$31,0000.0%2,2900.0%0.00%0.0%
Q2 2022$31,000
-16.2%
2,2900.0%0.00%0.0%
Q1 2022$37,0000.0%2,2900.0%0.00%0.0%
Q4 2021$37,000
+8.8%
2,2900.0%0.00%0.0%
Q3 2021$34,000
-26.1%
2,2900.0%0.00%
-50.0%
Q2 2021$46,000
-13.2%
2,2900.0%0.00%0.0%
Q1 2021$53,000
-7.0%
2,2900.0%0.00%
-33.3%
Q4 2020$57,000
-40.0%
2,2900.0%0.00%
-25.0%
Q3 2020$95,000
-13.6%
2,2900.0%0.00%
-20.0%
Q2 2020$110,000
-20.3%
2,290
+4.4%
0.01%
-37.5%
Q1 2020$138,000
-49.3%
2,1930.0%0.01%
-33.3%
Q4 2019$272,000
+94.3%
2,193
+3.8%
0.01%
+100.0%
Q3 2019$140,000
-16.7%
2,1120.0%0.01%
-25.0%
Q2 2019$168,000
-16.8%
2,112
+16.8%
0.01%
-11.1%
Q1 2019$202,000
+11.0%
1,8080.0%0.01%
-10.0%
Q4 2018$182,000
-20.2%
1,8080.0%0.01%
-9.1%
Q3 2018$228,000
+50.0%
1,8080.0%0.01%
+57.1%
Q2 2018$152,000
-25.1%
1,808
+193.5%
0.01%
-56.2%
Q1 2014$203,0006160.02%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders